JP2009515927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515927A5 JP2009515927A5 JP2008540580A JP2008540580A JP2009515927A5 JP 2009515927 A5 JP2009515927 A5 JP 2009515927A5 JP 2008540580 A JP2008540580 A JP 2008540580A JP 2008540580 A JP2008540580 A JP 2008540580A JP 2009515927 A5 JP2009515927 A5 JP 2009515927A5
- Authority
- JP
- Japan
- Prior art keywords
- asymptomatic
- latent
- heart failure
- use according
- pde iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110689.6 | 2005-11-14 | ||
| EP05110689 | 2005-11-14 | ||
| PCT/EP2006/068231 WO2007054514A2 (en) | 2005-11-14 | 2006-11-08 | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515927A JP2009515927A (ja) | 2009-04-16 |
| JP2009515927A5 true JP2009515927A5 (https=) | 2010-01-07 |
| JP5312034B2 JP5312034B2 (ja) | 2013-10-09 |
Family
ID=37744668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540580A Active JP5312034B2 (ja) | 2005-11-14 | 2006-11-08 | 無症候性（潜在性）心不全の治療のためのｐｄｅｉｉｉ阻害剤の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070112010A1 (https=) |
| EP (2) | EP3210605A1 (https=) |
| JP (1) | JP5312034B2 (https=) |
| CN (2) | CN102784394A (https=) |
| AR (1) | AR056800A1 (https=) |
| AU (1) | AU2006310997B2 (https=) |
| CA (1) | CA2629367C (https=) |
| DK (1) | DK1951227T3 (https=) |
| ES (1) | ES2631879T3 (https=) |
| HU (1) | HUE033546T2 (https=) |
| PL (1) | PL1951227T3 (https=) |
| TW (1) | TW200735874A (https=) |
| WO (1) | WO2007054514A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| FI20040674A0 (fi) | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP2279009A4 (en) * | 2008-05-05 | 2011-09-21 | Univ Rochester | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE |
| CN102223882B (zh) | 2008-11-25 | 2016-02-03 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂 |
| NL1037569C2 (en) * | 2009-12-18 | 2011-06-21 | Eurovet Animal Health B V | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use. |
| EP3167876B1 (en) * | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| EP3021832B9 (en) | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| CA2930033C (en) | 2013-12-04 | 2022-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) * | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| EA039250B1 (ru) * | 2016-06-01 | 2021-12-23 | Бёрингер Ингельхайм Ветмедика Гмбх | Применение пимобендана для уменьшения размера сердца и замедления начала клинических симптомов у пациентов с асимптоматической сердечной недостаточностью вследствие митрального порока сердца |
| WO2022073954A1 (en) | 2020-10-08 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan in the anaesthesia of non-human mammals |
| TW202508593A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES482789A0 (es) | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona |
| GB8400863D0 (en) * | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| EP0220044B1 (en) * | 1985-10-17 | 1991-01-30 | Smith Kline & French Laboratories Limited | 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives |
| US4868182A (en) | 1986-11-05 | 1989-09-19 | Merrell Dow Pharmaceuticals Inc. | Enhancement of prazosin |
| DE3804490A1 (de) * | 1988-02-12 | 1989-08-24 | Heumann Pharma Gmbh & Co | Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| GB8824458D0 (en) | 1988-10-19 | 1988-11-23 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| WO2003012030A2 (en) * | 2001-08-01 | 2003-02-13 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
| EP1579862A1 (en) * | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
-
2006
- 2006-11-08 HU HUE06829958A patent/HUE033546T2/hu unknown
- 2006-11-08 DK DK06829958.5T patent/DK1951227T3/en active
- 2006-11-08 AU AU2006310997A patent/AU2006310997B2/en active Active
- 2006-11-08 CN CN201210144177XA patent/CN102784394A/zh active Pending
- 2006-11-08 CA CA2629367A patent/CA2629367C/en active Active
- 2006-11-08 JP JP2008540580A patent/JP5312034B2/ja active Active
- 2006-11-08 WO PCT/EP2006/068231 patent/WO2007054514A2/en not_active Ceased
- 2006-11-08 EP EP17165100.3A patent/EP3210605A1/en not_active Withdrawn
- 2006-11-08 ES ES06829958.5T patent/ES2631879T3/es active Active
- 2006-11-08 PL PL06829958T patent/PL1951227T3/pl unknown
- 2006-11-08 CN CNA2006800424125A patent/CN101309685A/zh active Pending
- 2006-11-08 EP EP06829958.5A patent/EP1951227B1/en active Active
- 2006-11-10 AR ARP060104928A patent/AR056800A1/es not_active Application Discontinuation
- 2006-11-13 TW TW095141963A patent/TW200735874A/zh unknown
- 2006-11-14 US US11/559,467 patent/US20070112010A1/en not_active Abandoned
-
2010
- 2010-07-07 US US12/831,657 patent/US20100273807A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515927A5 (https=) | ||
| US9901568B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
| JP2022180461A5 (https=) | ||
| JP2010536849A5 (https=) | ||
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| JP2010518122A5 (https=) | ||
| JP2009537554A5 (https=) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2008524120A5 (https=) | ||
| JP2011502997A5 (https=) | ||
| SI2582683T1 (en) | Treatment of gout and hyperuricemia | |
| JP2011522816A5 (https=) | ||
| JP2005508371A5 (https=) | ||
| NZ584686A (en) | Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate | |
| JP2014521658A5 (https=) | ||
| JP2012021025A (ja) | メロキシカムを含む組成物 | |
| JP2010520246A5 (https=) | ||
| JP2018527305A5 (https=) | ||
| JP2014521641A5 (https=) | ||
| JP2015505295A5 (https=) | ||
| JP2008516004A5 (https=) | ||
| JP2006515299A5 (https=) | ||
| JP2009518415A5 (https=) | ||
| WO2007054514A3 (en) | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure |